Trials / Active Not Recruiting
Active Not RecruitingNCT06818812
A Study to Evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation
A Phase 1, Open-Label, Multicenter Study of INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation
- Status
- Active Not Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 30 (actual)
- Sponsor
- Incyte Corporation · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | INCB186748 | INCB186748 will be administered at protocol defined dose. |
| DRUG | Cetuximab | Cetuximab will be administered at protocol defined dose. |
| DRUG | GEMNabP | GEMNabP will be administered at protocol defined dose. |
| DRUG | mFOLFIRINOX | mFOLFIRINOX will be administered at protocol defined dose. |
Timeline
- Start date
- 2025-03-27
- Primary completion
- 2027-03-27
- Completion
- 2027-03-27
- First posted
- 2025-02-10
- Last updated
- 2026-03-23
Locations
9 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06818812. Inclusion in this directory is not an endorsement.